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AbstrAct
Objective: The relationship between variants of the leptin gene (LEP) and obesity and metabolic 
biomarkers was investigated in Brazilian individuals. Subjects and methods: One-hundred-ten 
obese (BMI > 30 kg/m2) and 100 non-obese individuals (145 women and 65 men, aged 49 ± 14 
years) were randomly selected. Plasma leptin, glycemia, serum lipid measurements and LEP 
-2548G>A and 3’HVR polymorphisms were analyzed. Results: The LEP -2548GG genotype was 
associated with a 2.2% and 2.0% increase in BMI (p = 0.009) and plasma leptin (p = 0.031), res-
pectively. 3’HVR I/II (classes I/I+I/II) genotypes contributed with 1.8% of BMI values (p = 0.046). 
LEP I/G combined genotypes (I/IGG, I/IGA and I/IIGG) were associated with obesity, and increa-
sed BMI, waist circumference, leptin and triglycerides (p < 0.05). These relationships were found 
in women (p < 0.05) but not in men. LEP I/G combined genotypes were not associated with 
hypertension, hyperglycemia, dyslipidemia and coronary artery disease. Conclusions: LEP I/G 
combined genotypes are associated with obesity-related metabolic biomarkers and phenotype 
in a gender-dependent manner. Arq Bras Endocrinol Metab. 2010;54(3):282-8
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rEsUMO
Objetivo: A relação entre as variantes do gene da leptina (LEP) e obesidade e biomarcadores 
metabólicos foi investigada em indivíduos brasileiros. Sujeitos e métodos: Cento e dez indiví-
duos obesos (IMC > 30 kg/m2) e 100 não obesos (145 mulheres e 65 homens, idade 49 ± 14 anos) 
foram selecionados aleatoriamente. Leptina plasmática, glicemia, lípides séricos e polimorfis-
mos LEP -2548G>A e 3’HVR foram analisados. Resultados: O genótipo -2548GG foi associado 
com aumento de 2,2% e 2,0% no IMC (p = 0,009) e leptina plasmática (p = 0,031), respectiva-
mente, enquanto os genótipos 3´HVR I/II (classes I/I+I/II) contribuíram com 1,8% dos valores 
de IMC (p = 0,046). Os genótipos combinados LEP I/G (I/IGG, I/IGA e I/IIGG) foram associados 
com obesidade e IMC aumentado, circunferência abdominal, leptina e triglicérides aumentados 
(p < 0,05). Essas relações foram encontradas em mulheres (p < 0,05), mas não em homens. Os 
genótipos LEP I/G combinados não foram associados com hipertensão, hiperglicemia, dislipi-
demia e doença arterial coronariana. Conclusões: Genótipos combinados LEP I/G são associa-
dos com biomarcadores metabólicos e fenótipo de obesidade de forma gênero-dependente. Arq 
Bras Endocrinol Metab. 2010;54(3):282-8
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IntrODUctIOn
Leptin is a metabolic and neuroendocrine hormone produced and released mainly by adipocytes (1). 
Several systemic effects are attributed to leptin such 
as body mass control, lipid and glucose metabolism, 
thermogenesis, angiogenesis, immunity, reproductive, en-
docrine and cardiovascular functions, among other (2). 
Increased leptin is associated with adiposity and it is 
expected to reduce food intake and increase energy ex-
penditure by binding to leptin receptors that further 
activate the hypothalamic melanocortin pathway and 
control body fat stores (3). 
Several studies have suggested that variants in the 
leptin gene (LEP) may be important in the pathophysi-
ology of human obesity (4-6). A common single nucle-
otide polymorphism (SNP) within the 5’ promoter re-
gion (-2548G>A) of the LEP has been associated with 
variations in plasma leptin and body mass index (BMI) 
in obese individuals (6-9). 
Microsatellite markers such as the highly variable 
tetranucleotide repeat (TTTC)n located in the 3’-flank-
ing region of the LEP (3’HVR) has also been associ-
ated with obesity-related traits and leptin plasma levels 
(6,10,11). However, the relation of this variant with 
other polymorphisms in the LEP gene on metabolic 
and obesity-related characteristics remains to be inves-
tigated. 
In this study, the relationship between LEP 3´HVR 
and -2548G>A variants and obesity-related phenotype 
and metabolic biomarkers was investigated in a sample 
of the Brazilian population. 
sUbJEcts AnD MEtHODs
study population
Two-hundred-ten unrelated individuals were randomly 
selected from Instituto Dante Pazzanese de Cardiolo-
gia (IDPC), Sao Paulo, Brazil. These individuals were 
declared to have European ancestry (non-African) by 
physical examination, however lack of relationship be-
tween color and genomic ancestry have been found in 
Brazilian samples (12). Sample size was estimated as 
267 individuals considering 50% the frequency of LEP 
alleles related with obesity (95% confidence level, 5% 
confidence interval, and over 20,000 population size). 
Individuals with thyroid, liver or kidney diseases, evalu-
ated by clinical and laboratory analyses, and pregnant 
women were not included in this sample. 
Anthropometric measurements, such as BMI, waist 
circumference (WC) and waist-to-hip ratio (WHR) 
were taken from each participant. Individuals with BMI 
≥ 30 kg/m² were classified as obese and those with sys-
tolic/diastolic blood pressure over 140/90 mmHg or 
under lowering-pressure therapy were considered hy-
pertensive. Individuals with fasting glycemia > 100 mg/dL 
were considered hyperglycemic. Cigarette smoking was 
considered when individuals smoked 3 or more ciga-
rettes/day. Sedentary life style was considered when 
individuals practiced less than a 30 min walk 3 times a 
week. The presence of coronary artery disease (CAD) 
was investigated by coronary angiography. The study 
protocol was approved by the Local Ethics Committees 
(Institute of Cardiology Dante Pazzanese and School 
of Pharmaceutical Sciences, University of Sao Paulo). 
biomarker analysis
Blood samples were collected from each participant af-
ter a 12-hour fasting for serum chemistry tests. Glu-
cose, triglycerides, and total cholesterol and high-den-
sity lipoprotein (HDL) cholesterol were measured by 
enzymatic-colorimetric assays using a Roche-Hitachi 
912 automated analyzer (Hitachi, Nakakojo, Japan). 
Low-density lipoprotein (LDL) and very low-density 
lipoprotein (VLDL) cholesterol were calculated. Apoli-
poproteins AI (apoAI) and B (apoB) were determined 
in serum by nephelometry. Plasma leptin was deter-
mined by an ELISA method (Alexis Biochemical/Ven-
dor BioAgency, Sao Paulo, Brazil). The atherogenic 
index of plasma (AIP) calculated as log (triglycerides/
HDL cholesterol), and ApoB/ApoAI ratio were used 
for evaluation of thecardiovascular risk.
DnA genotyping
Genomic DNA was extracted from 1 mL EDTA-anti-
coagulated whole blood by a salting-out method (13). 
LEP -2548G>A and 3´HVR polymorphisms were gen-
otyped by polymerase chain reaction (PCR) and frag-
ment analysis as previously described (8,11). The ac-
curacy of the genotyping was evaluated by performing 
duplicate analysis of 20% samples randomly selected. 
Moreover, heterozygous LEP -2458G>A and 3´HVR 
samples were included as genotype controls in each run.
statistical analysis
LEP 3´HVR alleles were grouped in class I (short) and 
class II (long) as previously described (11). LEP com-
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bined genotypes were formed by grouping 3´HVR and 
-2548G>A genotypes. The agreement of genotype fre-
quencies with Hardy-Weinberg equilibrium (HWE) ex-
pectations was tested by the chi-square test. The linkage 
disequilibrium between LEP variants was estimated using 
the SNPAnalyzer software (D’ index) (14). Relationships 
between the genotypes and categorical variables were 
evaluated by the chi-square test or Exact Fisher test.
Continuous variables without normal distribution 
(BMI, WC, leptin, glucose and lipid profile) were log 
transformed prior to the statistical analysis. Anthropo-
metric and blood chemistry parameters were compared 
between LEP variants by One-way ANOVA and t-test. 
Pearson’s correlation coefficients were used to estimate 
the association between continuous variables. 
Logistic and linear regression analyses were used 
to verify the relationships between obesity, LEP vari-
ants and other variables such as BMI, WC, WHR and 
leptin. The models were adjusted by the covariates of 
age, gender, hypertension, hyperglycemia, CAD, ciga-
rette smoking and sedentary life style. Statistical tests 
were performed by SAS System for Windows software 
version 8.02 (SAS Institute Inc, 1999-2001, Cary, NC, 
USA). The level of significance was considered p < 0.05.
rEsUlts
Anthropometric, demographic and biochemical data of 
the studied group are shown in table 1. Four women 
refused to inform their ages. One woman and one man 
did not have their waist and hip measured. Obese in-
dividuals (BMI > 30 kg/m2) had higher means of age 
and anthropometric data (BMI, WC and WHR) as well 
as higher frequencies of hypertension, hyperglycemia, 
cigarette smoking, sedentary life style and CAD when 
compared with the non-obese group (p < 0.05). Plasma 
leptin was also higher in obese than in the non-obese 
group (p < 0.05). 
LEP 3´HVR class I/I and I/II genotypes were 
more frequent in obese (I/I: 24%, I/II: 56%) than in 
non-obese individuals (I/I: 21%, I/II: 44%, p = 0.043) 
(Table 1). For -2548G>A polymorphism, the frequen-
cy of the GG genotype in obese (41%) was similar to 
that found in non-obese (28%) (p = 0.090) individuals. 
Both LEP 3´HVR and -2548G>A variants were under 
HWE in this sample (Table 1). A linkage disequilibrium 
was found between these polymorphisms (D’ index = 
0.7113). We found nine LEP combined genotypes 
that were grouped as: I/G (I/IGG + I/IGA+ I/
IIGG); II/A (I/IIAA + II/IIAA + II/IIGA); and 
others (I/IAA + I/IIGA + II/IIGG). Obese indi-
viduals had higher frequencies of I/G combined geno-
types (45%) than non-obese subjects (27%, p = 0.018). 
Results from univariate logistic regression analysis 
are shown in table 2. Variables were adjusted by the co-
variates of age, hypertension, hyperglycemia, cigarette 
smoking, sedentary life style and CAD due to their as-
sociation with obesity previously demonstrated (13). 
Individuals carrying 3´HVR class I/II genotype had 3 
times higher risk for obesity (OR: 3.12, 95% CI: 1.21 
- 8.08) compared to those with class II/II genotype (p 
= 0.019). The carriers of -2548GA and GG genotypes 
had, respectively, 4 times (OR: 4.75, 95% CI: 1.30 – 
17.36) and 8 times (OR: 8.695, 95% CI: 2.22 -34.05) 
table 1. Anthropometric and laboratory data of the study group
non-obese Obese p-value
Number of individuals 110 100
Age, years 45 ± 15 52 ± 13 < 0.001
Gender, women 59% 41% 0.378
Hypertension 9% 72% < 0.001
Hyperglycemia 1% 25% < 0.001
Coronary artery disease 8% 14% < 0.001
Cigarette smoking 30% 43% 0.020
Sedentary life stile 59% 75% 0.015
Body mass index, kg/m2* 24.2 ± 3.1 35.6 ± 4.7 < 0.001
Waist circumference, cm 87.3 ± 10.8 109.6 ± 11.4 < 0.001
Waist-hip ratio 0.87 ± 0.07 0.92 ± 0.06 < 0.001
Plasma leptin, ng/mL* 12.0 ± 12.0 35.1 ± 21.3 < 0.001
LEP 3´HVR
Class I/I genotype
Class I/II genotype
Class II/II genotype
HWE (p-value)
21% (23)
44% (48)
35% (39)
0.256
24% (24)
56% (56)
20% (20)
0.223
0.043
LEP -2548G > A
GG genotype
GA genotype
AA genotype
HWE (p-value)
28% (31)
52% (57)
20% (22)
0.649
41% (41)
47% (47)
12% (12)
0.793
0.090
LEP combined genotypes
I/G (I/IGG + I/IGA + I/IIGG)
II/A (I/IIAA + II/IIAA + II/IIGA)
Others (I/IAA + I/IIGA + II/IIGG)
27% (30)
31% (34)
42% (46)
45% (45)
19% (19)
36% (36)
0.018
Continuous variables are presented as mean ± SD and compared by t-test. Categorical variables 
were compared by chi-square test. HWE, Hardy-Weinberg equilibrium. Four women refused to 
inform their ages. One man and a woman did not have their waist and hip measured. Obesity: 
body mass index ≥ 30 kg/m². Hypertension: blood pressure > 140/90 mmHg or use of lowering-
pressure therapy. Hyperglycemia: blood glucose > 100 mg/dL. Cigarette smoking: 3 cigarettes/
day. Sedentary life style: to practice less than a 30 min walk 3 times a week. (*) Values were log 
transformed.
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table 2. Univariate logistic regression analysis of the LEP variants 
associated with obesity 
Variables categories Odds ratio 95% cI p-value 
3´HVR genotypes Class II/II
Class I/II
Class I/I
1.00
3.12
1.89
-
1.21 - 8.08
0.60 - 5.98
-
0.019
0.278
-2548G > A genotypes AA
GA
GG
1.00
4.75
8.69
-
1.30 - 17.36
2.22 - 34.05
-
0.019
0.002
LEP combined 
genotypes
II/A
I/G
Other
1.00
3.97
2.62
-
1.30 - 5.55
0.69 - 2.85
-
0.012
0.068
Variables were adjusted for covariates: age, gender, hypertension, hyperglycemia, coronary artery 
disease, cigarette smoking and sedentary life stile. CI, confidence interval. I/G genotypes, I/IGG + 
I/IGA + I/IIGG; II/A genotypes, I/IIAA+II/IIAA+II/GA; Other genotypes, I/IAA + I/IIGA + II/II + GG. 
more risk for obesity than the -2548AA genotype carriers 
(p < 0.05). In addition, the risk for obesity was 4 times 
higher in I/G carriers (OR: 3.97, 95% CI: 1.30 - 5.55) 
than in those carrying II/A (p = 0.012). 
Multivariate logistic regression analysis using step-
wise criteria for selection of the genetic variables related 
with obesity was also tested. After adjustment for co-
variates (age, hypertension, hyperglycemia, cigarette 
smoking, sedentary life style and CAD), only the LEP 
-2548GG genotype was associated with an increased 
risk for obesity (OR: 9.43, 95% CI: 1.84 – 48.31; 
p = 0.007) (data not shown). 
The relationship between LEP variants and anthro-
pometric and blood chemistry variables were also inves-
tigated in this study (Table 3). Individuals carrying I/G 
genotypes had higher serum triglycerides when com-
pared to the II/A carriers (p < 0.05). AIP values were 
also higher in I/G carriers than in those carrying other 
genotypes (p < 0.05). We investigated whether the 
relationship between LEP variants and these variables 
were influenced by gender, considering that leptin and 
obesity-related traits (BMI, WC, WHR) were higher in 
women than in men (p < 0.05) (data not shown). I/G 
genotypes were associated with higher WC, BMI and 
leptin values in women but not in men (Figure 1). 
Univariate linear regression analysis showed that the 
variations in log-transformed values of the BMI were 
partially explained by LEP 3´HVR class I/II genotype 
(1.80%, p = 0.046) and -2548GG genotype (2.20%, 
p = 0.009), as indicated by the determinant coeffi-
cient (R2) (Table 4). Moreover, only 2% of variation 
in log-transformed plasma leptin is explained by LEP 
-2548GG genotype (p = 0.031). Regression coef-
ficients (estimates) indicate that the carriers of the 
table 3. Anthropometric and blood chemistry data in individuals carrying 
the LEP genotypes
Variables I/G II/A Others p-value
Number of individuals 75 53 82
Body mass index, kg/m2* 30.9 ± 6.9 28.0 ± 6.4 29.6 ± 7.1 0.070
Waist circumference, cm 101 ± 16 95 ± 15 96 ± 15 0.056
Waist-hip ratio, % 91 ± 7 89 ± 7 88 ± 7 0.082
Leptin, ng/mL* 26.1 ± 20.6 17.8 ± 15.6 23.4 ± 14.7 0.228
Glucose, mg/dL* 104 ± 27 101 ± 96 103 ± 30 0.850
Total cholesterol, mg/dL* 215 ± 42 214 ± 47 204 ± 42 0.203
HDL-c, mg/dL* 53 ± 13 56 ± 14 55 ± 15 0.461
LDL-c, mg/dL* 132 ± 34 129 ± 41 122 ± 34 0.222
VLDL-c, mg/dL* 30 ± 11 28 ± 15 27 ± 13 0.101
Triglycerides, mg/dL* 153 ± 60a 147 ± 83b 132 ± 65a,b 0.039
ApoAI, mg/dL* 136 ± 26 137 ± 26 136 ± 26 0.995
ApoB, mg/dL* 112 ± 27 108 ± 28 102 ± 24 0.099
ApoB/ApoAI ratio* 0.84 ± 0.25 0.82 ± 0.28 0.77 ± 0.21 0.202
AIP [log (triglycerides/
HDL-c)]*
0.44 ± 0.23a 0.37 ± 0.29a,b 0.34 ± 0.27b 0.048
Results are presented as mean ± SD and compared by one-way ANOVA. Values in a row with 
different superscript letters are significantly different, p < 0.05 (Tukey’s test). AIP, atherogenic 
index of plasma; ApoAI, apolipoprotein I; ApoB, apolipoprotein B; HDL-c, high-density 
lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; VLDL-c, very low-density 
lipoprotein cholesterol. (*) log-transformed data. 
 
WC WHR BMI Leptin
0
25
50
75
100
125
I/G
II/A
LEP genotypes
*
*
*
Un
its
 
WC WHR BMI Leptin
0
25
50
75
100
125
I/G
II/A
LEP genotypes
Un
its
Figure 1. Anthropometric and plasma leptin values in women (A) and men 
(B) carrying LEP I/G and II/A combined genotypes. Waist circumference 
(WC, cm), waist-hip ratio (WHR, %), body mass index (BMI, kg/m2), 
plasma leptin (ng/mL). Values presented as mean ± SD are compared by 
t-test (* p < 0.05).
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table 4. Univariate linear regression analysis of the variables associated 
with LEP variants
Dependent 
variables LEP variants r
2 Estimate 
(sE) p-value 
Waist 
circumference
3´HVR class  
I/II genotype
-2548GG genotype
I/G genotypes
0.0121
0.0077
0.0081
3.74 (2.07)
4.15 (2.67)
3.70 (2.30)
0.073
0.122
0.109
Waist-hip ratio 3´HVR class  
I/II genotype
-2548GG genotype
I/G genotypes
0.0037
0.0011
0.0061
0.01 (0.01)
0.01 (0.01)
0.01 (0.01)
0.884
0.565
0.590
Body mass index* 3´HVR class  
I/II genotype
-2548GG genotype
I/G genotypes
0.0180
0.0220
0.0131
0.03 (0.01)
0.04 (0.02)
0.02 (0.01)
0.046
0.009
0.077
Leptin* 3´HVR class  
I/II genotype
-2548GG genotype
I/G genotypes
0.0099
0.0200
0.0177
0.11 (0.06)
0.20 (0.07)
0.12 (0.06)
0.060
0.031
0.054
Variables were adjusted to the covariates: age, gender, hypertension, hyperglycemia, CAD, 
cigarette smoking and sedentary file stile. SE, standard error. (*) log-transformed data.
3´HVR class I/II genotype had log-transformed BMI 
0.03 more than the non-carriers. Moreover, log plasma 
leptin was 0.11 higher in 3´HVR class I/II genotype 
and 0.20 higher in -2548GG genotype in comparison 
with those carrying other genotypes (Table 4).
We also investigated whether the LEP variants were 
associated with hypertension, hyperglycemia, dyslipid-
emia and CAD but no relationship was found between 
these clinical conditions and LEP variants in this sample 
(data not shown).
DIscUssIOn
The LEP variants evaluated in this sample were asso-
ciated with obesity. Individuals carrying the -2548GG 
genotype have higher risk for increased BMI than car-
riers of the -2548GA+AA genotypes. Moreover, the 
-2548GG genotype carriers have 8 times more risk 
for obesity than the non-carriers suggesting that LEP 
-2458G>A polymorphism maybe a good predictor for 
obesity.
The association between LEP -2548G>A polymor-
phism and increased BMI was also found in overweight 
Europeans and Taiwanese Aborigines with extreme 
obesity (15,16). We have also found a relationship 
between the -2548G>A variant and increased plasma 
leptin and BMI in Brazilian women (8). It is important 
to mention that the relationship between -2548GG 
genotype and obesity was found in recessive and co-
dominant models, but not in the dominant model (16). 
In addition, common variants located in the 5´region 
of the LEP, including -2548G>A, were associated with 
increased BMI in men (17). The presence of the GG 
genotype was also associated with increase in BMI and 
weight gain in persons treated with olanzapine (18-20). 
However, no association was found between this poly-
morphism and obesity in a population-based case con-
trol study in Spain (21).
In this study, LEP -2458GG genotype was also 
shown to be a predictor for increased plasma leptin. 
This result confirms the findings from other investiga-
tions that showed an association between -2458AA (-/-) 
genotype and lower leptin levels in Caucasian obese 
girls and diabetic individuals from China (22,23). Con-
versely, as commented previously, -2458AA genotype 
was associated with increased plasma leptin in obese in-
dividuals (15). Moreover, carriers of this genotype had 
lesser decrease in circulating leptin after gastric banding 
surgery (24). The results from these studies are sug-
gestive that the relationship between LEP -2548G>A 
and obesity-related phenotypes may be influenced by 
sample characteristics such as gender, sample size, po-
pulation and other.
The variant -2548G>A has been implicated in the 
regulation of LEP mRNA expression and consequently 
leptin plasma levels (25). Gong and cols. (26) have de-
scribed two repetitive sequences MER11 and Alu lo-
cated at the LEP promoter (-2514 to 1545) that may 
regulate LEP expression (26). In addition, the 3-kb 
5´-flanking region contains several putative binding 
sites for known transcription factors, including CREB, 
GRE, Sp1, LP1, C/EBP and TATA motifs (26,27). A 
Sp1 functional placental enhancer was found within the 
MER11 repetitive element suggesting that expression of 
leptin is the result of insertion of this element (28). Re-
cently, Moreno-Aliaga and cols. (29) reported that the 
Sp1 binding site has a key role in the transcriptional acti-
vation of the LEP promoter by insulin-mediated glucose 
metabolism (29). Whether the -2548G>A variant locat-
ed close to a Sp1 binding site (-2539) also modulates 
the transcription of the LEP remains to be investigated.
The role of leptin in body fat control is mediated by 
leptin receptors (LEPR) in specific hypothalamic cen-
ters that stimulate the production of anorectic peptides 
and inhibit the orexigenic molecules (30). LEPR gene 
(LEPR) polymorphisms have also been associated with 
increased BMI and other obesity-related characteristics 
in several populations (4,31-33). The combination of 
LEP -2548G>A and LEPR Q223R variants was related 
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to a 58% increase in obesity risk in another sample of 
our population (34). Therefore, the relationship be-
tween LEP -2548G>A and increased BMI found in 
this study may be due to its linkage to Q223R or other 
LEPR polymorphisms. 
The LEP 3´HVR is a (TTTC)n tetranucleotide re-
peat located at the 3’ end of the LEP that has been as-
sociated with increased risk for obesity and high plasma 
leptin levels as well (10-11). These effects may be due 
to the linkage of the 3’HVR with -2548G>A variant. 
The presence of the LEP I/G genotypes was associ-
ated with an increased risk for obesity-related pheno-
type (BMI and WC) and the biomarker of plasma leptin. 
The influence of I/G variant was further demonstrated 
to be related to gender, even though this variable did 
not affect the distribution of the LEP I/G genotypes. 
Accordingly, it has been shown that the association be-
tween a LEP variant (A19G) and risk for obesity was 
restricted to females from the Atherosclerosis Risk in 
Communities (ARIC) Study (35).
Differences in plasma glucose were not related to 
LEP I/G genotypes, confirming the lack of association 
between these variants and hyperglycemia. This result 
suggests that LEP variants may not be implicated in 
glucose homeostasis. Accordingly, insulin responses to 
glucose and insulin sensitivity were similar among Jap-
anese carriers of LEP 3´HVR genotypes (36). Serum 
triglycerides and AIP values were found to be higher 
in LEP I/G carriers suggesting a possible role of LEP 
combined genotypes in lipid metabolism and cardiovas-
cular risk. However, association analyses did not show 
relationship of the LEP variants with dyslipidemia and 
CAD evaluated by coronary angiography. Therefore, 
further investigations are necessary to evaluate these 
data in larger populations. 
The lack of association between hypertension or 
cardiovascular disease and LEP 3´HVR has been also 
shown in other populations (37-39). Therefore, the as-
sociation between obesity and hypertension and other 
risk factors for CAD previously found in our sample (8) 
seems to be independent of the LEP I/G genotypes.
It is noteworthy that the results from this study may 
be influenced by the limited sample size, which reduced 
the power of the statistical tests. Therefore studies with 
larger samples from the Brazilian population are neces-
sary to confirm our findings.
In conclusion, -2548G>A and 3´HVR variants of 
the LEP gene are in linkage disequilibrium, and I/G 
combined genotypes are associated with obesity-re lated 
biomarkers and phenotype and it is likely that they con-
tribute to the regulation of circulating leptin and tri-
glycerides in a gender-dependent manner.
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